• Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision


Panexcell Clinical Laboratories: suspension of medicines over flawed studies

On 24 July 2020, EMA’s human medicines committee (CHMP) recommended the suspension of the marketing authorisations of generic medicines tested by Panexcell Clinical Laboratories Priv. Ltd at its site in Mumbai, India.

The recommendation came after Austrian and German inspectors found irregularities in how the company carried out bioequivalence studies. These are studies used to show that a generic medicine produces the same amount of active substance in the body as the reference medicine.

The inspectors found samples from different patients that were exceptionally similar and an instance of personnel documenting the wrong room temperature for the area where samples were being processed. These findings raise serious concerns about the company’s quality management system and the reliability of data from that site.

The CHMP looked at all medicines tested by Panexcell on behalf of EU companies and found none for which adequate data were available from other sources.

The Committee therefore recommended that all medicines authorised in the EU on the basis of bioequivalence studies conducted by Panexcell be suspended from the market. To lift the suspension, companies in the EU relying on data from Panexcell must provide alternative data demonstrating bioequivalence.

Medicines that were being evaluated for authorisation on the basis of data from Panexcell will not be granted authorisation in the EU.

EMA and national authorities will continue working closely together to ensure that studies on EU medicines are carried out to the highest standards and that companies comply with all aspects of Good Clinical Practice (GCP). If companies do not meet required standards, authorities will take whatever measures necessary to ensure the integrity of data used to approve EU medicines.

The CHMP's recommendation was sent to the European Commission for a legally binding decision.

Key facts

About this medicine
Approved name
International non-proprietary name (INN) or common name
  • atazanavir
  • atazanavir sulfate
  • Amoxicillin trihydrate
  • iron sucrose
  • amoxicillin
  • azithromycin dihydrate
  • carbocisteine
  • trimethoprim
About this procedure
Current status
European Commission final decision
Reference number
Article 31 referrals

This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

Authorisation model
Nationally authorised product(s)
Key dates and outcomes
CHMP opinion date
EC decision date

All documents

Procedure started

Opinion provided by Committee for Medicinal Products for Human Use

European Commission final decision

  • List item

    Panexcell Article-31 referral - Panexcell Clinical Laboratories: suspension of medicines over flawed studies (PDF/134.88 KB)

    First published: 24/07/2020
    Last updated: 22/10/2020

  • List item

    Panexcell Article-31 referral - Annex I (PDF/133.07 KB)


    First published: 22/10/2020

  • List item

    Panexcell Article-31 referral - Annex III (PDF/75.92 KB)

    First published: 22/10/2020

  • List item

    Panexcell Article-31 referral - Annex II (PDF/93.86 KB)

    First published: 22/10/2020

  • List item

    Panexcell Article-31 referral - Assessment report (PDF/241.72 KB)


    First published: 06/10/2020

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.


    How useful was this page?

    Add your rating
    3 ratings
    1 rating
    1 rating